Abstract
Fever above 38C that occurs in patients with acute neurosurgical diseases appears to worsen secondary brain injury and ultimate neurologic outcomes. Laboratory investigations are quite clear regarding the adverse effects of fever in terms not only of functional outcomes, but also histologic and neurochemical injury. Several preliminary clinical studies also suggest worsened neurologic outcomes in patients who are febrile compared to those who are not. Unfortunately, however, a large prospective study of 428 patients with acute neurosurgical diseases has shown that fever is extraordinarily common during the first seven days after subarachnoid hemorrhage, stroke, and TBI. The ability to eliminate fever in most of these patients during the first five to seven days after their injury would seem desirable. Based on a phase-I trial, it appears that intravascular cooling is a promising new method for avoiding fever in the neurosurgical ICU.
Keywords: Hypothermia, Fever
Current Pharmaceutical Design
Title: Therapeutic Moderate Hypothermia and Fever
Volume: 7 Issue: 15
Author(s): D. W. Marion
Affiliation:
Keywords: Hypothermia, Fever
Abstract: Fever above 38C that occurs in patients with acute neurosurgical diseases appears to worsen secondary brain injury and ultimate neurologic outcomes. Laboratory investigations are quite clear regarding the adverse effects of fever in terms not only of functional outcomes, but also histologic and neurochemical injury. Several preliminary clinical studies also suggest worsened neurologic outcomes in patients who are febrile compared to those who are not. Unfortunately, however, a large prospective study of 428 patients with acute neurosurgical diseases has shown that fever is extraordinarily common during the first seven days after subarachnoid hemorrhage, stroke, and TBI. The ability to eliminate fever in most of these patients during the first five to seven days after their injury would seem desirable. Based on a phase-I trial, it appears that intravascular cooling is a promising new method for avoiding fever in the neurosurgical ICU.
Export Options
About this article
Cite this article as:
Marion W. D., Therapeutic Moderate Hypothermia and Fever, Current Pharmaceutical Design 2001; 7 (15) . https://dx.doi.org/10.2174/1381612013397302
DOI https://dx.doi.org/10.2174/1381612013397302 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Common Cellular and Molecular Mechanisms Underlying Alzheimer’s Disease and Type 2 Diabetes: A Knowledge-Driven Approach
CNS & Neurological Disorders - Drug Targets Experimental and Clinical Application of Plasmid DNA in the Field of Central Nervous Diseases
Current Gene Therapy Microcirculation in Sepsis: New Perspectives
Current Vascular Pharmacology The Use of Antiepileptic Drugs in Paediatric Neurosurgical Conditions
Current Pharmaceutical Design Convection Enhanced Delivery of Macromolecules for Brain Tumors
Current Drug Discovery Technologies Botulinum Toxin as a Neuro-Relearning Drug Tool in Motor Paralytic Disorders
Current Drug Therapy A Needle-Free Approach for Topical Immunization: Antigen Delivery via Vesicular Carrier System(s)
Current Medicinal Chemistry Cell-and Gene-based Therapeutic Approaches for Neurological Deficits in Mucopolysaccharidoses
Current Pharmaceutical Biotechnology Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design α2-Antiplasmin on Cardiovascular Diseases
Current Pharmaceutical Design A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology Therapeutic Utilisations of Vasopressin and Oxytocin in Mood Disorders
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Clinical Trials with Intracerebral Convection-Enhanced Delivery of Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials Raxofelast, (±)5-(Acetyloxy)-2,3-dihydro-4,6,7-trimethyl-2-benzofuranacetic Acid: A New Antioxidant to Modulate the Inflammatory Response During Ischemia-Reperfusion Injury and Impaired Wound Healing
Mini-Reviews in Medicinal Chemistry Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Cross Talk Among Leukocytes, Platelets, and Endothelial Cells and its Relevance to Atherosclerosis and Coronary Heart Disease
Current Nutrition & Food Science Microdialysis in the Human Brain and its Potential Role in the Development and Clinical Assessment of Drugs
Current Medicinal Chemistry Nitric Oxide, Peroxynitrite, Peroxynitrous Acid, Nitroxyl, Nitrogen Dioxide, Nitrous Oxide: Biochemical Mechanisms and Bioaction
Current Bioactive Compounds